European CHMP recommends approval of lumasiran (Oxlumo) for the treatment of primary hyperoxaluria type 1

Primary hyperoxaluria is a rare inherited disorder characterised by the overproduction of oxalate. Lumasiran has been shown to reduce plasma oxalate levels and 24-hour urinary oxalate excretion compared to placebo, as observed during a 6-month double-blind RCT.

Source:

European Medicines Agency